1164PEfficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients

1164PEfficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2018-10, Vol.29 (suppl_8)
Hauptverfasser: Hernandez, M, Neninger, E, Santiesteban, E, Camacho, K, Hernandez, N, Amador, R, Acosta, S, Gonzalez, Y, Jimenez, Y, Corella, M, Ortiz, R A, Bello, L, Calana, A, Pichs, G, Cala, M, Flores, Y, Viada, C, Robaina, M, Crombet, T
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue suppl_8
container_start_page
container_title Annals of oncology
container_volume 29
creator Hernandez, M
Neninger, E
Santiesteban, E
Camacho, K
Hernandez, N
Amador, R
Acosta, S
Gonzalez, Y
Jimenez, Y
Corella, M
Ortiz, R A
Bello, L
Calana, A
Pichs, G
Cala, M
Flores, Y
Viada, C
Robaina, M
Crombet, T
description
doi_str_mv 10.1093/annonc/mdy288.037
format Article
fullrecord <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdy288_037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdy288.037</oup_id><sourcerecordid>10.1093/annonc/mdy288.037</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdy288_0373</originalsourceid><addsrcrecordid>eNqVj8tOwzAQRS0EEuHxAezmA0hrJ2kar1ERSxbdW4Njg5Efke1UhBWfjqPyA2xmdHTvSHMIeWB0wyhvt-h98HLrxqUZhg1t9xekYrue1wPt2CWpKG_aer9ru2tyk9InpbTnDa_ID2N993rQ2kiUCwQNEWXIswsO3yBE8MYV_J5XPCUYg1QZv5QFTJCUDH6srfEK8oeKOC2gyw2OJ_RSjVB-qpNDa0GqMuzs30GuUYQJs1E-pztypdEmdf-3b8nj8-H49FKHeRJTNA7jIhgVq6U4W4qzpSiW7T_rvybzXw0</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1164PEfficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Hernandez, M ; Neninger, E ; Santiesteban, E ; Camacho, K ; Hernandez, N ; Amador, R ; Acosta, S ; Gonzalez, Y ; Jimenez, Y ; Corella, M ; Ortiz, R A ; Bello, L ; Calana, A ; Pichs, G ; Cala, M ; Flores, Y ; Viada, C ; Robaina, M ; Crombet, T</creator><creatorcontrib>Hernandez, M ; Neninger, E ; Santiesteban, E ; Camacho, K ; Hernandez, N ; Amador, R ; Acosta, S ; Gonzalez, Y ; Jimenez, Y ; Corella, M ; Ortiz, R A ; Bello, L ; Calana, A ; Pichs, G ; Cala, M ; Flores, Y ; Viada, C ; Robaina, M ; Crombet, T</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy288.037</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2018-10, Vol.29 (suppl_8)</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Hernandez, M</creatorcontrib><creatorcontrib>Neninger, E</creatorcontrib><creatorcontrib>Santiesteban, E</creatorcontrib><creatorcontrib>Camacho, K</creatorcontrib><creatorcontrib>Hernandez, N</creatorcontrib><creatorcontrib>Amador, R</creatorcontrib><creatorcontrib>Acosta, S</creatorcontrib><creatorcontrib>Gonzalez, Y</creatorcontrib><creatorcontrib>Jimenez, Y</creatorcontrib><creatorcontrib>Corella, M</creatorcontrib><creatorcontrib>Ortiz, R A</creatorcontrib><creatorcontrib>Bello, L</creatorcontrib><creatorcontrib>Calana, A</creatorcontrib><creatorcontrib>Pichs, G</creatorcontrib><creatorcontrib>Cala, M</creatorcontrib><creatorcontrib>Flores, Y</creatorcontrib><creatorcontrib>Viada, C</creatorcontrib><creatorcontrib>Robaina, M</creatorcontrib><creatorcontrib>Crombet, T</creatorcontrib><title>1164PEfficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVj8tOwzAQRS0EEuHxAezmA0hrJ2kar1ERSxbdW4Njg5Efke1UhBWfjqPyA2xmdHTvSHMIeWB0wyhvt-h98HLrxqUZhg1t9xekYrue1wPt2CWpKG_aer9ru2tyk9InpbTnDa_ID2N993rQ2kiUCwQNEWXIswsO3yBE8MYV_J5XPCUYg1QZv5QFTJCUDH6srfEK8oeKOC2gyw2OJ_RSjVB-qpNDa0GqMuzs30GuUYQJs1E-pztypdEmdf-3b8nj8-H49FKHeRJTNA7jIhgVq6U4W4qzpSiW7T_rvybzXw0</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Hernandez, M</creator><creator>Neninger, E</creator><creator>Santiesteban, E</creator><creator>Camacho, K</creator><creator>Hernandez, N</creator><creator>Amador, R</creator><creator>Acosta, S</creator><creator>Gonzalez, Y</creator><creator>Jimenez, Y</creator><creator>Corella, M</creator><creator>Ortiz, R A</creator><creator>Bello, L</creator><creator>Calana, A</creator><creator>Pichs, G</creator><creator>Cala, M</creator><creator>Flores, Y</creator><creator>Viada, C</creator><creator>Robaina, M</creator><creator>Crombet, T</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20181001</creationdate><title>1164PEfficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients</title><author>Hernandez, M ; Neninger, E ; Santiesteban, E ; Camacho, K ; Hernandez, N ; Amador, R ; Acosta, S ; Gonzalez, Y ; Jimenez, Y ; Corella, M ; Ortiz, R A ; Bello, L ; Calana, A ; Pichs, G ; Cala, M ; Flores, Y ; Viada, C ; Robaina, M ; Crombet, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdy288_0373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hernandez, M</creatorcontrib><creatorcontrib>Neninger, E</creatorcontrib><creatorcontrib>Santiesteban, E</creatorcontrib><creatorcontrib>Camacho, K</creatorcontrib><creatorcontrib>Hernandez, N</creatorcontrib><creatorcontrib>Amador, R</creatorcontrib><creatorcontrib>Acosta, S</creatorcontrib><creatorcontrib>Gonzalez, Y</creatorcontrib><creatorcontrib>Jimenez, Y</creatorcontrib><creatorcontrib>Corella, M</creatorcontrib><creatorcontrib>Ortiz, R A</creatorcontrib><creatorcontrib>Bello, L</creatorcontrib><creatorcontrib>Calana, A</creatorcontrib><creatorcontrib>Pichs, G</creatorcontrib><creatorcontrib>Cala, M</creatorcontrib><creatorcontrib>Flores, Y</creatorcontrib><creatorcontrib>Viada, C</creatorcontrib><creatorcontrib>Robaina, M</creatorcontrib><creatorcontrib>Crombet, T</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hernandez, M</au><au>Neninger, E</au><au>Santiesteban, E</au><au>Camacho, K</au><au>Hernandez, N</au><au>Amador, R</au><au>Acosta, S</au><au>Gonzalez, Y</au><au>Jimenez, Y</au><au>Corella, M</au><au>Ortiz, R A</au><au>Bello, L</au><au>Calana, A</au><au>Pichs, G</au><au>Cala, M</au><au>Flores, Y</au><au>Viada, C</au><au>Robaina, M</au><au>Crombet, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1164PEfficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients</atitle><jtitle>Annals of oncology</jtitle><date>2018-10-01</date><risdate>2018</risdate><volume>29</volume><issue>suppl_8</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Oxford University Press</pub><doi>10.1093/annonc/mdy288.037</doi></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2018-10, Vol.29 (suppl_8)
issn 0923-7534
1569-8041
language eng
recordid cdi_oup_primary_10_1093_annonc_mdy288_037
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title 1164PEfficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T22%3A26%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1164PEfficacy%20of%20racotumomab%20or%20nimotuzumab%20vs%20docetaxel%20as%20second-line%20therapy%20for%20advanced%20non-small%20cell%20lung%20cancer%20patients&rft.jtitle=Annals%20of%20oncology&rft.au=Hernandez,%20M&rft.date=2018-10-01&rft.volume=29&rft.issue=suppl_8&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy288.037&rft_dat=%3Coup%3E10.1093/annonc/mdy288.037%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdy288.037&rfr_iscdi=true